Evaluation of D-Fi for the Treatment of Wounds Due to DEB
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 32
- Registration Number
- NCT06892639
- Locations
- 🇺🇸
Thomas Jefferson University Dept of Dermatology and Cutaneous Biology, Philadelphia, Pennsylvania, United States
🇺🇸Stanford University School of Medicine, Dermatology, Redwood City, California, United States
🇺🇸Mission Dermatology, Santa Margarita, California, United States
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Biological: FCX-007 (dabocemagene autoficel; see below for FCX-007 description)
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 6
- Registration Number
- NCT04213261
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Dell Children's Medical Group, Austin, Texas, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
- Conditions
- SclerodermaMorpheaScleroderma, Localized
- Interventions
- Genetic: FCX-013
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 1
- Registration Number
- NCT03740724
- Locations
- 🇺🇸
Paddington Testing Co., Inc., Philadelphia, Pennsylvania, United States
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- Conditions
- Epidermolysis Bullosa Dystrophica, Recessive
- Interventions
- Genetic: FCX-007
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 6
- Registration Number
- NCT02810951
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia
- Conditions
- Age-related DysphoniaDysphonia Resulting From Vocal Fold Scarring
- Interventions
- Drug: PlaceboBiological: Azficel-T (autologous fibroblasts)
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 21
- Registration Number
- NCT02120781
- Locations
- 🇺🇸
Dept of Otolaryngology, Stanford Univ Medical Center, Stanford, California, United States
🇺🇸Surgery/Head and Neck, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸NYU Langone Medical Center, New York, New York, United States
Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars
- Conditions
- Restrictive Burn Scars
- Interventions
- Biological: Autologous fibroblastsBiological: placebo sterile saline
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 5
- Registration Number
- NCT01858753
- Locations
- 🇺🇸
Richard M. Fairbanks Burn Center, Indianapolis, Indiana, United States
🇺🇸Center for Innovation in Restorative Medicine, Pittsburgh, Pennsylvania, United States
🇺🇸Division of Burns and Trauma, Jackson Memorial Hospital, Miami, Florida, United States
Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency
- Conditions
- Interdental Papillary Insufficiency
- Interventions
- Biological: Autologous Human Fibroblasts (azficel-T)
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 13
- Registration Number
- NCT00655889
- Locations
- 🇺🇸
Perio-Health Professionals, Inc., Houston, Texas, United States
Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases
- Conditions
- Facial Wrinkles and Creases
- Interventions
- Biological: Autologous Human Fibroblasts (azficel-T)
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 50
- Registration Number
- NCT00654654
- Locations
- 🇺🇸
The Laser Institute for Dermatology, Santa Monica, California, United States
🇺🇸Rhonda Rand, M.D., Inc., Beverly Hills, California, United States
🇺🇸Dermatology, Laser and Vein Specialists of the Carolinas, Charlotte, North Carolina, United States
Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles
- Conditions
- Bilateral Nasolabial Fold Wrinkles
- Interventions
- Biological: Autologous Human Fibroblasts (azficel-T)Biological: Placebo
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 218
- Registration Number
- NCT00655356
- Locations
- 🇺🇸
Brighton Medical Corporation, Beverly Hills, California, United States
🇺🇸Therapeutics Clinical Research, San Diego, California, United States
🇺🇸Charlottesville Medical Research, Charlottesville, Virginia, United States
Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles
- Conditions
- Bilateral Nasolabial Fold Wrinkles
- Interventions
- Biological: PlaceboBiological: Autologous Human Fibroblast (azficel-T)
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 203
- Registration Number
- NCT00649428
- Locations
- 🇺🇸
Silverburg Surgical & Medical Group, Newport Beach, California, United States
🇺🇸Dermatology Research Institute, LLC, Coral Gables, Florida, United States
🇺🇸Total Skin & Beauty Dermatology Center, PC, Birmingham, Alabama, United States